| Literature DB >> 26411412 |
Balraj Mittal1, Sonam Tulsyan2, Surendra Kumar2, Rama Devi Mittal3, Gaurav Agarwal4.
Abstract
Cytochrome 450 (CYP450) designates a group of enzymes abundant in smooth endoplasmic reticulum of hepatocytes and epithelial cells of small intestines. The main function of CYP450 is oxidative catalysis of various endogenous and exogenous substances. CYP450 are implicated in phase I metabolism of 80% of drugs currently in use, including anticancer drugs. They are also involved in synthesis of various hormones and influence hormone-related cancers. CYP450 genes are highly polymorphic and their variants play an important role in cancer risk and treatment. Association studies and meta-analyses have been performed to decipher the role of CYP450 polymorphisms in cancer susceptibility. Cancer treatment involves multimodal therapies and evaluation of CYP450 polymorphisms is necessary for pharmacogenetic assessment of anticancer therapy outcomes. In addition, CYP450 inhibitors are being evaluated for improved pharmacokinetics and oral formulation of several anticancer drugs.Entities:
Keywords: Anticancer therapy; CYP450 inhibitors; Drug metabolism; Genetic predisposition; Pharmacogenetics
Mesh：
Substances：
Year: 2015 PMID： 26411412 DOI： 10.1016/bs.acc.2015.06.003
Source DB: PubMed Journal: Adv Clin Chem ISSN： 0065-2423 Impact factor: 5.394